CLINICAL-RESULTS WITH RESOVIST - A PHASE-2 CLINICAL-TRIAL

被引：174

作者：

REIMER, P ^{[1
]}

RUMMENY, EJ ^{[1
]}

DALDRUP, HE ^{[1
]}

BALZER, T ^{[1
]}

TOMBACH, B ^{[1
]}

BERNS, T ^{[1
]}

PETERS, PE ^{[1
]}

机构：

[1] UNIV MUNSTER,DEPT SURG,D-48129 MUNSTER,GERMANY

来源：

RADIOLOGY | 1995年 / 195卷 / 02期

关键词：

IRON; LIVER; MR; LIVER NEOPLASMS; MAGNETIC RESONANCE (MR); CONTRAST ENHANCEMENT;

D O I：

10.1148/radiology.195.2.7724772

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

PURPOSE: To investigate the superparamagnetic iron oxide (Resovist) designed for contrast material-enhanced magnetic resonance imaging of the liver. MATERIALS AND METHODS: A phase 2 trial was performed in 33 patients with no more than five known focal solid liver lesions. Resovist was administered intravenously at doses of 4, 8, and 16 mu mol of iron per kilogram of body weight. Postcontrast 1.0-T imaging was started 30 minutes after injection. RESULTS: Resovist significantly (P less than or equal to .05) decreased liver signal intensity and increased lesion-to-liver contrast-to-noise ratio (C/N) and the number of detectable liver lesions: fast spin-echo (SE) (echo time, 90 msec) precontrast C/N, 11.7 +/- 7.9 [standard deviation]; postcontrast [8-mu mol Fe/kg] C/N, 29.2 +/- 14.2). The dose of 8 mu mol Fe/kg was sufficient for the detection of focal liver lesions, and T2-weighted fast SE with an echo time of 90 msec was the overall best pulse sequence. CONCLUSION: Resovist is a safe contrast agent, and a dose of 8 mu mol Fe/kg is sufficient to enhance detection of focal liver lesions at T2-weighted fast SE MR imaging.

引用

页码：489 / 496

页数：8

共 25 条

[1]

Brasch R.C., New directions in the development of MR imaging contrast media, Radiology, 183, pp. 1-11, (1992)

[2]

Weissleder R., Hahn P.F., Stark D.D., Et al., Superparamagnetic iron oxide: Enhanced detection of focal splenic tumors with MR imaging, Radiology, 169, pp. 399-403, (1988)

[3]

Stark D.D., Weissleder R., Elizondo G., Et al., Superparamagnetic iron oxide: Clinical application as a contrast agent for MR imaging of the liver, Radiology, 168, pp. 297-301, (1988)

[4]

Ferrucci J.T., Stark D.D., Iron oxide-enhanced MR imaging of the liver and spleen: Review of the first 5 years, AJR, 155, pp. 943-950, (1990)

[5]

Marchal G.Y., Van Hecke P., Demaerel P., Et al., Detection of liver metastases with superparamagnetic iron oxides in 15 patients: Results of MR imaging at 1.5 T, AJR, 152, pp. 771-775, (1989)

[6]

Duda S.H., Laniado M., Kopp A.F., Et al., Superparamagnetic iron oxide: Detection of focal liver lesions at high-field-strength MR imaging, JMRI, 4, pp. 309-314, (1994)

[7]

Hamm B., Staks T., Taupitz M., Et al., Contrast-enhanced MR imaging of liver and spleen: First experience in humans with a new superparamagnetic iron oxide, JMRI, 4, pp. 659-668, (1994)

[8]

Hamm B., Staks T., Taupitz M., A new superparamagnetic iron oxide contrast agent for magnetic resonance imaging, Invest Radiol, 29, (1994)

[9]

Winter III T.C., Freeny P.C., Nghiem H.V., Et al., MR imaging with IV superparamagnetic iron oxide: Efficacy in the detection of focal hepatic lesions, AJR, 161, pp. 1191-1198, (1993)

[10]

Hennig J., Nauerth A., Friedburg H., RARE imaging: A fast method for clinical MR, Magn Reson Med, 3, pp. 823-833, (1986)

← 1 2 3 →